324 filings
8-K
SKYE
Skye Bioscience Inc
10 Jun 24
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
9:27am
EFFECT
SKYE
Skye Bioscience Inc
20 May 24
Notice of effectiveness
12:15am
EFFECT
SKYE
Skye Bioscience Inc
20 May 24
Notice of effectiveness
12:15am
424B3
SKYE
Skye Bioscience Inc
17 May 24
Prospectus supplement
4:27pm
S-3
SKYE
Skye Bioscience Inc
Shelf registration
10 May 24
4:19pm
EFFECT
0vixyopf09r odzn
29 Apr 24
Notice of effectiveness
12:15am
POS AM
0v3k3u7uxgszx acqb4
24 Apr 24
Prospectus update (post-effective amendment)
4:40pm
EFFECT
ibc6bkdy 98h1v
11 Apr 24
Notice of effectiveness
12:15am
424B3
x4tk6i
10 Apr 24
Prospectus supplement
4:40pm
CERT
oqlcxpf0k7 hex
10 Apr 24
Certification of approval for exchange listing
9:58am
8-A12B
mm4lk
10 Apr 24
Registration of securities on exchange
7:00am
8-K
c83fqqt9
3 Apr 24
Regulation FD Disclosure
5:07pm
D
dmgcxf wyva
26 Mar 24
$40.00 mm in equity, sold $40.00 mm, 13 investors
6:04pm
8-K
3ytllg7w6chrw5
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
u9u6 rg5pl0a
4 Mar 24
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
4:23pm